Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 21st January 2022
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Collaboration to discover canine therapeutic antibodies
"This strategic partnership is another example of our commitment to address unmet needs in the animal health market" - Stephen Martin, Boehringer Ingelheim Animal Health.

Boehringer Ingelheim and MabGenesis will combine their expertise to develop new products.   

Boehringer Ingelheim and biopharmaceutical firm MabGenesis are joining forces to discover new canine monoclonal antibodies for potential therapeutic treatments. 

The partnership will see MabGenesis apply its unique technology platform to discover first class antibodies against targets of interest selected by Boehringer Ingelheim. 

While the terms of the agreement have not been disclosed, Boehringer will have the right to develop and commercialise the resulting products for the veterinary market. 

Katsuhiro Shinjo, chief executive officer of MabGenesis, said: “We are excited to partner with global animal health leader Boehringer Ingelheim as we feel we bring complementary expertise to this collaboration. 

“The combination of our innovative discovery platform, MOURA Library and IMPACT, and Boehringer Ingelheim’s capability and industry leadership will surely lead to the discovery of innovative canine therapeutic antibodies bringing benefits to animal health.”

Boehringer Ingelheim said that strengthening partnership to accelerate innovation is key in its research and development strategy. 

Stephen Martin, head of research at Boehringer Ingelheim Animal Health, said: “We believe that collaboration and shared innovation can lead to groundbreaking solutions to better predict, prevent, detect and treat diseases.

"This strategic partnership is another example of our commitment to address unmet needs in the animal health market with the aim to improve the lives of animals and humans.”

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.